Allergan Plc (AGN) 235.96 $AGN
Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Allergan to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Thu Sep 01, 6:30AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that Brent Saunders, Allergan's CEO and President, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 11:45 a.m. ET at the Grand Hyatt in New York, NY.
AGN: 235.96 (-1.80), MS: 31.89 (-0.02)
After Yesterday's Decline of 2.01%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 11:55AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $231.31 to a high of $237.50. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $235.14 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 235.96 (-1.80)
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
PR Newswire - Wed Aug 31, 7:00AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 235.96 (-1.80), GNRX: 24.40 (-0.14), PRGO: 90.75 (-0.50), AXGN: 8.89 (-0.10), AKRX: 26.47 (-0.21), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), AMPH: 18.56 (-0.43), NVS: 79.38 (+1.11)
Top Research Reports for Apple, Allergan & Occidental Petroleum
Sheraz Mian - Zacks Investment Research - Mon Aug 29, 9:49AM CDT
Top Research Reports for Apple, Allergan & Occidental Petroleum
AGN: 235.96 (-1.80), TAP: 104.21 (+1.74), OXY: 77.51 (+0.67), AAPL: 107.73 (+1.00)
Markets Right Now: Health care pulls stocks lower again
AP - Thu Aug 25, 3:09PM CDT
NEW YORK (AP) — The latest on developments in global financial markets (all times local):
AGN: 235.96 (-1.80)
Watch for Allergan to Potentially Rebound After Falling 1.33% Yesterday
Comtex SmarTrend(R) - Thu Aug 25, 11:54AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $238.72 to a high of $244.27. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $240.86 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 235.96 (-1.80)
Asian shares waver in thin trading after Wall Street decline
By ELAINE KURTENBACH - AP - Wed Aug 24, 9:58PM CDT
NEW YORK (AP) — Shares wavered in thin but volatile trading in Asia on Thursday, following a bleak day on Wall Street led by declines in health-care stocks as outrage mounts over steep price hikes for Mylan's EpiPens. Investors are awaiting a speech by Federal Reserve chair Janet Yellen's on Friday.
AGN: 235.96 (-1.80)
Business Highlights
By The Associated Press - AP - Wed Aug 24, 4:24PM CDT
___
AGN: 235.96 (-1.80), AZN: 33.31 (+0.71), PFE: 34.77 (+0.09)
Pfizer on buying spree with AstraZeneca antibiotics deal
By LINDA A. JOHNSON - AP - Wed Aug 24, 4:11PM CDT
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move its headquarters, on paper, to Allergan's base in lower-tax Ireland.
AGN: 235.96 (-1.80), AZN: 33.31 (+0.71), PFE: 34.77 (+0.09), ANAC: 99.06 (-0.14)
Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 235.96 (-1.80), CEMP: 22.11 (-0.18), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 235.96 (-1.80), ZTS: 51.26 (+0.15), VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), VRX.TO: 37.34 (-0.75)
Pfizer spends $14B on Medivation in cancer fight
By TOM MURPHY and LINDA A. JOHNSON - AP - Mon Aug 22, 10:46AM CDT
Pfizer will pay about $14 billion to buy cancer drug developer Medivation in a cash deal aimed at fortifying its hold in one of the hottest and most lucrative areas of medicine.
MDVN: 80.85 (-0.08), AGN: 235.96 (-1.80), ABT: 42.09 (-0.21), PFE: 34.77 (+0.09)
Research and Markets - Depression Epidemiology and Patient-Based Market Forecasts 2016 Featuring Lundbeck, Allergan and Johnson & Johnson
PR Newswire Europe - Wed Aug 17, 10:10AM CDT
Research and Markets has announced the addition of the "Depression: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" [http://www.researchandmarkets.com/research/hpjp9n/depression] report to their offering.
AGN: 235.96 (-1.80), JNJ: 119.32 (+0.24)
Global Premature Ejaculation Treatment Market Growth of 9.65% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Allergan, Bayer, Dong-A Pharmaceutical - Research and Markets
BusinessWire - Wed Aug 17, 4:12AM CDT
Research and Markets has announced the addition of the "Global Premature Ejaculation Treatment Market 2016-2020" report to their offering.
AGN: 235.96 (-1.80)
Global Silicone Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, Ashland, Rogers Corp - Research and Markets
BusinessWire - Tue Aug 16, 7:49AM CDT
Research and Markets has announced the addition of the "Silicone Market -By Type (Fluids, Elastomers, Resins, Gels, Others) By End-user (Industrial, Electronics, Machinery, Aerospace, Medical, others) Application -Forecast(2016-2021)" report to their offering.
AGN: 235.96 (-1.80)
Why is Time (TIME) Stock Popping Today?
Madeleine Johnson - Zacks Investment Research - Mon Aug 15, 12:22PM CDT
On Monday, shares of magazine publisher Time Inc. (TIME) are popping, up over 6% in late-morning trading after Jana Partners LLC, a New York-based hedge fund, announced a new, 5 million share position in the media company.
AGN: 235.96 (-1.80), TIME: 14.22 (+0.21), HTZ: 49.59 (+0.36), CSC: 49.08 (+1.45), CAG: 46.64 (+0.62), PFE: 34.77 (+0.09), EXPE: 112.05 (-1.08)
Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Allergan to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Thu Sep 01, 6:30AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that Brent Saunders, Allergan's CEO and President, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 11:45 a.m. ET at the Grand Hyatt in New York, NY.
AGN: 235.96 (-1.80), MS: 31.89 (-0.02)
After Yesterday's Decline of 2.01%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 11:55AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $231.31 to a high of $237.50. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $235.14 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 235.96 (-1.80)
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
PR Newswire - Wed Aug 31, 7:00AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 235.96 (-1.80), GNRX: 24.40 (-0.14), PRGO: 90.75 (-0.50), AXGN: 8.89 (-0.10), AKRX: 26.47 (-0.21), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), AMPH: 18.56 (-0.43), NVS: 79.38 (+1.11)
Top Research Reports for Apple, Allergan & Occidental Petroleum
Sheraz Mian - Zacks Investment Research - Mon Aug 29, 9:49AM CDT
Top Research Reports for Apple, Allergan & Occidental Petroleum
AGN: 235.96 (-1.80), TAP: 104.21 (+1.74), OXY: 77.51 (+0.67), AAPL: 107.73 (+1.00)
Markets Right Now: Health care pulls stocks lower again
AP - Thu Aug 25, 3:09PM CDT
NEW YORK (AP) — The latest on developments in global financial markets (all times local):
AGN: 235.96 (-1.80)
Watch for Allergan to Potentially Rebound After Falling 1.33% Yesterday
Comtex SmarTrend(R) - Thu Aug 25, 11:54AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $238.72 to a high of $244.27. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $240.86 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 235.96 (-1.80)
Asian shares waver in thin trading after Wall Street decline
By ELAINE KURTENBACH - AP - Wed Aug 24, 9:58PM CDT
NEW YORK (AP) — Shares wavered in thin but volatile trading in Asia on Thursday, following a bleak day on Wall Street led by declines in health-care stocks as outrage mounts over steep price hikes for Mylan's EpiPens. Investors are awaiting a speech by Federal Reserve chair Janet Yellen's on Friday.
AGN: 235.96 (-1.80)
Business Highlights
By The Associated Press - AP - Wed Aug 24, 4:24PM CDT
___
AGN: 235.96 (-1.80), AZN: 33.31 (+0.71), PFE: 34.77 (+0.09)
Pfizer on buying spree with AstraZeneca antibiotics deal
By LINDA A. JOHNSON - AP - Wed Aug 24, 4:11PM CDT
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move its headquarters, on paper, to Allergan's base in lower-tax Ireland.
AGN: 235.96 (-1.80), AZN: 33.31 (+0.71), PFE: 34.77 (+0.09), ANAC: 99.06 (-0.14)
Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 235.96 (-1.80), CEMP: 22.11 (-0.18), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 235.96 (-1.80), ZTS: 51.26 (+0.15), VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), VRX.TO: 37.34 (-0.75)
Pfizer spends $14B on Medivation in cancer fight
By TOM MURPHY and LINDA A. JOHNSON - AP - Mon Aug 22, 10:46AM CDT
Pfizer will pay about $14 billion to buy cancer drug developer Medivation in a cash deal aimed at fortifying its hold in one of the hottest and most lucrative areas of medicine.
MDVN: 80.85 (-0.08), AGN: 235.96 (-1.80), ABT: 42.09 (-0.21), PFE: 34.77 (+0.09)
Research and Markets - Depression Epidemiology and Patient-Based Market Forecasts 2016 Featuring Lundbeck, Allergan and Johnson & Johnson
PR Newswire Europe - Wed Aug 17, 10:10AM CDT
Research and Markets has announced the addition of the "Depression: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" [http://www.researchandmarkets.com/research/hpjp9n/depression] report to their offering.
AGN: 235.96 (-1.80), JNJ: 119.32 (+0.24)
Global Premature Ejaculation Treatment Market Growth of 9.65% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Allergan, Bayer, Dong-A Pharmaceutical - Research and Markets
BusinessWire - Wed Aug 17, 4:12AM CDT
Research and Markets has announced the addition of the "Global Premature Ejaculation Treatment Market 2016-2020" report to their offering.
AGN: 235.96 (-1.80)
Global Silicone Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, Ashland, Rogers Corp - Research and Markets
BusinessWire - Tue Aug 16, 7:49AM CDT
Research and Markets has announced the addition of the "Silicone Market -By Type (Fluids, Elastomers, Resins, Gels, Others) By End-user (Industrial, Electronics, Machinery, Aerospace, Medical, others) Application -Forecast(2016-2021)" report to their offering.
AGN: 235.96 (-1.80)
Why is Time (TIME) Stock Popping Today?
Madeleine Johnson - Zacks Investment Research - Mon Aug 15, 12:22PM CDT
On Monday, shares of magazine publisher Time Inc. (TIME) are popping, up over 6% in late-morning trading after Jana Partners LLC, a New York-based hedge fund, announced a new, 5 million share position in the media company.
AGN: 235.96 (-1.80), TIME: 14.22 (+0.21), HTZ: 49.59 (+0.36), CSC: 49.08 (+1.45), CAG: 46.64 (+0.62), PFE: 34.77 (+0.09), EXPE: 112.05 (-1.08)
